, in development with the University of Oxford, may also generate investor concern. The biopharma firm's Phase 3 study has been kept on hold after a participant in the UK was suspected of a serious adverse reaction.
The bill aims to transfer powers previously held by the EU to regulate issues such as food standards and environment policy to the four UK nations - England, Wales, Scotland, and Northern Ireland - and to keep trade free-flowing after Brexit.
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite: